Pneumococcal vaccination and chronic respiratory diseases

References

• CelliBRBarnesPJExacerbations of chronic obstructive pulmonary diseaseEur Respir J20072961224123817540785
   PubMed Web of Science ®Google Scholar
• DivoMCoteCde TorresJPComorbidities and risk of mortality in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2012186215516122561964
   PubMed Web of Science ®Google Scholar
• SethiSInfection as a comorbidity of COPDEur Respir J20103561209121520513910
   PubMed Web of Science ®Google Scholar
• SethiSMurphyTFInfection in the pathogenesis and course of chronic obstructive pulmonary diseaseN Engl J Med2008359222355236519038881
   PubMed Web of Science ®Google Scholar
• WedzichaJAMackayAJSinghRCOPD exacerbations: impact and preventionBreathe201396434440
   Google Scholar
• LinJLiYTianHCosts and health care resource utilization among chronic obstructive pulmonary disease patients with newly acquired pneumoniaClinicoecon Outcomes Res2014634935625075195
   PubMedGoogle Scholar
• RyanMSuayaJAChapmanJDStasonWBShepardDSThomasCPIncidence and cost of pneumonia in older adults with COPD in the United StatesPLoS One2013810e7588724130749
   PubMed Web of Science ®Google Scholar
• BontenMJHuijtsSMBolkenbaasMPolysaccharide conjugate vaccine against pneumococcal pneumonia in adultsN Engl J Med2015372121114112525785969
   PubMed Web of Science ®Google Scholar
• VosTAllenCAroraMGlobal, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015Lancet2016388100531545160227733282
   PubMed Web of Science ®Google Scholar
• WangHNaghaviMAllenCGlobal, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015Lancet2016388100531459154427733281
   PubMed Web of Science ®Google Scholar
• World Health OrganizationThe top 10 causes of death2014 Available from: http://www.who.int/mediacentre/factsheets/fs310/enAccessed December 31, 2016
   Google Scholar
• European Respiratory SocietyEuropean Lung White BookLausanne, SwitzerlandERS2016
   Google Scholar
• SheaKMEdelsbergJWeyckerDFarkouhRAStruttonDRPeltonSIRates of pneumococcal disease in adults with chronic medical conditionsOpen Forum Infect Dis201411ofu02425734097
   PubMedGoogle Scholar
• WardBWBlackLIState and regional prevalence of diagnosed multiple chronic conditions among adults aged ≥18 years: United States, 2014MMWR Morb Mortal Wkly Rep2016652973573827467707
   PubMed Web of Science ®Google Scholar
• MullerovaHChigboCHaganGWThe natural history of community-acquired pneumonia in COPD patients: a population database analysisRespir Med201210681124113322621820
   PubMed Web of Science ®Google Scholar
• TorresAPeetermansWEViegiGBlasiFRisk factors for community-acquired pneumonia in adults in Europe: a literature reviewThorax201368111057106524130229
   PubMed Web of Science ®Google Scholar
• InghammarMEngströmGKahlmeterGLjungbergBLöfdahlCGEgestenAInvasive pneumococcal disease in patients with an underlying pulmonary disorderClin Microbiol Infect201319121148115423464817
   PubMed Web of Science ®Google Scholar
• ShuklaSDMahmoodMQWestonSThe main rhinovirus respiratory tract adhesion site (ICAM-1) is upregulated in smokers and patients with chronic airflow limitation (CAL)Respir Res2017181628056984
   PubMed Web of Science ®Google Scholar
• ShuklaSDMullerHKLathamRSohalSSWaltersEHPlatelet- activating factor receptor (PAFr) is upregulated in small airways and alveoli of smokers and COPD patientsRespirology201621350451026662379
   PubMed Web of Science ®Google Scholar
• YawnBPLiYTianHZhangJArconaSKahlerKHInhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysisInt J Chron Obstruct Pulmon Dis2013829530423836970
   PubMed Web of Science ®Google Scholar
• WedzichaJABrillSEAllinsonJPDonaldsonGCMechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary diseaseBMC Med20131118123945277
   PubMed Web of Science ®Google Scholar
• SapeyEStockleyRACOPD exacerbations – 2: aetiologyThorax200661325025816517585
   PubMed Web of Science ®Google Scholar
• PapiABellettatoCMBraccioniFInfections and airway inflammation in chronic obstructive pulmonary disease severe exacerbationsAm J Respir Crit Care Med2006173101114112116484677
   PubMed Web of Science ®Google Scholar
• EllerJEdeASchabergTNiedermanMSMauchHLodeHInfective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung functionChest19981136154215489631791
   PubMed Web of Science ®Google Scholar
• AndreassenSLLiaaenEDStenforsNHenriksenAHImpact of pneumonia on hospitalizations due to acute exacerbations of COPDClin Respir J201481939923889911
   PubMed Web of Science ®Google Scholar
• SøgaardMMadsenMLøkkeAHilbergOSørensenHTThomsenRWIncidence and outcomes of patients hospitalized with COPD exacerbation with and without pneumoniaInt J Chron Obstruct Pulmon Dis20161145546527042038
   PubMed Web of Science ®Google Scholar
• MyintPKLoweDStoneRABuckinghamRJRobertsCMU.K. National COPD Resources and Outcomes Project 2008: patients with chronic obstructive pulmonary disease exacerbations who present with radiological pneumonia have worse outcome compared to those with non-pneumonic chronic obstructive pulmonary disease exacerbationsRespiration201182432032721597277
   PubMed Web of Science ®Google Scholar
• ZvezdinBMilutinovSKojicicMA postmortem analysis of major causes of early death in patients hospitalized with COPD exacerbationChest2009136237638019318666
   PubMed Web of Science ®Google Scholar
• PolskyDBonafedeMSuayaJAComorbidities as a driver of the excess costs of community-acquired pneumonia in U.S. commercially-insured working age adultsBMC Health Serv Res20121237923113880
   PubMed Web of Science ®Google Scholar
• AndrewsNJWaightPAGeorgeRCSlackMPMillerEImpact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and WalesVaccine201230486802680823000122
   PubMed Web of Science ®Google Scholar
• ArtzASErshlerWBLongoDLPneumococcal vaccination and revaccination of older adultsClin Microbiol Rev200316230831812692100
   PubMed Web of Science ®Google Scholar
• WaltersJASmithSPoolePGrangerRHWood-BakerRInjectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary diseaseCochrane Database Syst Rev201011CD00139021069668
   PubMed Web of Science ®Google Scholar
• WaltersJATangJNPoolePWood-BakerRPneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary diseaseCochrane Database Syst Rev20171CD00139028116747
   PubMed Web of Science ®Google Scholar
• HtarMTStuurmanALFerreiraGEffectiveness of pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-analyses of observational studiesPLoS One2017125e017798528542347
   PubMed Web of Science ®Google Scholar
• No authors listedPneumococcal vaccines WHO position paper: 2012Wkly Epidemiol Rec2012871412914424340399
   PubMedGoogle Scholar
• KhoieTTiernanRdeVoreNVaccines and Related Biological Products Advisory CommitteeFDA Briefing Document – Prevnar 13 (CV13): pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein)2011 Available from: https://pdfs.semanticscholar.org/d394/d5e91b28e01e28c89a81c312dd79b02007b9.pdfAccessed October 11, 2017
   Google Scholar
• deVoreNSummary basis for regulatory action [Prevnar 13/pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein)]2011 Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM287412.pdfAccessed October 1, 2017
   Google Scholar
• European Medicines AgencyCHMP variation assessment report [Prevenar 13]: type II variation EMEA/H/C/001104/II/00282011 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/001104/WC500119784.pdfAccessed October 1, 2017
   Google Scholar
• ClutterbuckEALazarusRYuLMPneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cellsJ Infect Dis201220591408141622457293
   PubMed Web of Science ®Google Scholar
• de RouxASchmöle-ThomaBSiberGRComparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memoryClin Infect Dis20084671015102318444818
   PubMed Web of Science ®Google Scholar
• ClutterbuckEASaltPOhSMarchantABeverleyPPollardAJThe kinetics and phenotype of the human B-cell response following immunization with a heptavalent pneumococcal-CRM conjugate vaccineImmunology2006119332833717067312
   PubMed Web of Science ®Google Scholar
• PollardAJPerrettKPBeverleyPCMaintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccinesNat Rev Immunol20099321322019214194
   PubMed Web of Science ®Google Scholar
• SiegristCAVaccine immunologyPlotkinSAOrensteinWOffittPAVaccines5th edAmsterdam, the NetherlandsElsevier20081736
   Google Scholar
• GoldblattDSouthernJAndrewsNThe immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50–80 yearsClin Infect Dis20094991318132519814624
   PubMed Web of Science ®Google Scholar
• GrabensteinJDManoffSBPneumococcal vaccines in adults: assessing the evolving evidenceVaccine201129376149615421763386
   PubMed Web of Science ®Google Scholar
• LazarusRClutterbuckEYuLMA randomized study comparing combined pneumococcal conjugate and polysaccharide vaccination schedules in adultsClin Infect Dis201152673674221367726
   PubMed Web of Science ®Google Scholar
• DransfieldMTNahmMHHanMKSuperior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2009180649950519556517
   PubMed Web of Science ®Google Scholar
• DransfieldMTHarndenSBurtonRLLong-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary diseaseClin Infect Dis2012555e35e4422652582
   PubMed Web of Science ®Google Scholar
• BaxendaleHEJohnsonMKeatingSMCirculating pneumococcal specific plasma and memory B cells in the elderly two years after pneumococcal conjugate versus polysaccharide vaccinationVaccine201028426915692220708698
   PubMed Web of Science ®Google Scholar
• BaxendaleHEKeatingSMJohnsonMSouthernJMillerEGoldblattDThe early kinetics of circulating pneumococcal-specific memory B cells following pneumococcal conjugate and plain polysaccharide vaccines in the elderlyVaccine201028304763477020471437
   PubMed Web of Science ®Google Scholar
• GrabensteinJDManoffSBPneumococcal polysaccharide 23-valent vaccine: long-term persistence of circulating antibody and immunogenicity and safety after revaccination in adultsVaccine201230304435444422542818
   PubMed Web of Science ®Google Scholar
• ChengAChangSYTsaiMSLong-term immune responses and comparative effectiveness of one or two doses of 7-valent pneumococcal conjugate vaccine (PCV7) in HIV-positive adults in the era of combination antiretroviral therapyJ Int AIDS Soc20161912063126829360
   PubMed Web of Science ®Google Scholar
• Ben-ShimolSGivon-LaviNLeibovitzERaizSGreenbergDDaganRNear-elimination of otitis media caused by 13-valent pneumococcal conjugate vaccine (PCV) serotypes in southern Israel shortly after sequential introduction of 7-valent/13-valent PCVClin Infect Dis201459121724173225159581
   PubMed Web of Science ®Google Scholar
• GreenbergDGivon-LaviNBen-ShimolSZivJBDaganRImpact of PCV7/PCV13 introduction on community-acquired alveolar pneumonia in children <5 yearsVaccine201533364623462926116251
   PubMed Web of Science ®Google Scholar
• GriffinMRMitchelEMooreMRWhitneyCGGrijalvaCGDeclines in pneumonia hospitalizations of children aged <2 years associated with the use of pneumococcal conjugate vaccines: Tennessee, 1998–2012MMWR Morb Mortal Wkly Rep2014634499599825375070
   PubMed Web of Science ®Google Scholar
• LauWCMurrayMEl-TurkiAImpact of pneumococcal conjugate vaccines on childhood otitis media in the United KingdomVaccine201533395072507926297875
   PubMed Web of Science ®Google Scholar
• MaromTTanAWilkinsonGSPiersonKSFreemanJLChonmaitreeTTrends in otitis media-related health care use in the United States, 2001–2011JAMA Pediatr20141681687524276262
   PubMed Web of Science ®Google Scholar
• LooJDConklinLFleming-DutraKESystematic review of the indirect effect of pneumococcal conjugate vaccine dosing schedules on pneumococcal disease and colonizationPediatr Infect Dis J201433Suppl 2S161S17124336058
   PubMed Web of Science ®Google Scholar
• van HoekAJSheppardCLAndrewsNJPneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in EnglandVaccine201432344349435524657717
   PubMed Web of Science ®Google Scholar
• Schmoele-ThomaBJacksonLAGreenbergRNImmunogenicity of 13-valent pneumococcal conjugate vaccine in immunocompetent older adults with stable underlying medical conditionsJ Vaccines Immun201532712
   Google Scholar
• van WerkhovenCHHuijtsSMBolkenbaasMGrobbeeDEBontenMJThe impact of age on the efficacy of 13-valent pneumococcal conjugate vaccine in elderlyClin Infect Dis201561121835183826265498
   PubMed Web of Science ®Google Scholar
• FalkenhorstGRemschmidtCHarderTHummers-PradierEWichmannOBogdanCEffectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) against pneumococcal disease in the elderly: systematic review and meta-analysisPLoS One2017121e016936828061505
   PubMed Web of Science ®Google Scholar
• Kraicer-MelamedHO’DonnellSQuachCThe effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50 years of age and older: a systematic review and meta-analysisVaccine201634131540155026899372
   PubMed Web of Science ®Google Scholar
• SuzukiMDhoubhadelBGIshifujiTSerotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design studyLancet Infect Dis201717331332128126327
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and PreventionUse of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP)MMWR Morb Mortal Wkly Rep2012614081681923051612
   PubMedGoogle Scholar
• KobayashiMBennettNMGierkeRIntervals between PCV13 and PPSV23 vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)MMWR Morb Mortal Wkly Rep2015643494494726334788
   PubMed Web of Science ®Google Scholar
• EspositoSBonanniPMaggiSRecommended immunization schedules for adults: clinical practice guidelines by the ESCMID Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAIDID)Hum Vaccin Immunother20161271777179427135390
   PubMed Web of Science ®Google Scholar
• GreenbergRNGurtmanAFrenckRWSequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60–64 years of ageVaccine201432202364237424606865
   PubMed Web of Science ®Google Scholar
• SchwarzTFFlamaingJRumkeHCA randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 yearsVaccine201129325195520221619909
   PubMed Web of Science ®Google Scholar
• FrenckRWJrGurtmanARubinoJRandomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adultsClin Vaccine Immunol20121981296130322739693
   PubMed Web of Science ®Google Scholar
• WoodheadMBlasiFEwigSGuidelines for the management of adult lower respiratory tract infections: full versionClin Microbiol Infect201117Suppl 6E1E59
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary DiseaseBethesda, MDGOLD2017
   Google Scholar
• MurphyTFSethiSBacterial infection in chronic obstructive pulmonary diseaseAm Rev Respir Dis19921464106710831416398
   PubMed Web of Science ®Google Scholar
• WilsonRA vicious circle hypothesis operating during infective exacerbations of chronic bronchitisMonaldi Arch Chest Dis19944921591648049702
   PubMedGoogle Scholar
• AlfagemeIVazquezRReyesNClinical efficacy of anti-pneumococcal vaccination in patients with COPDThorax200661318919516227328
   PubMed Web of Science ®Google Scholar
• FurumotoAOhkusaYChenMAdditive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung diseaseVaccine200826334284428918585831
   PubMed Web of Science ®Google Scholar
• PoolePJChackoEWood-BakerRWCatesCJInfluenza vaccine for patients with chronic obstructive pulmonary diseaseCochrane Database Syst Rev20061CD00273316437444
   PubMed Web of Science ®Google Scholar
• ChristensonBPauksenKSylvanSPEffect of influenza and pneumococcal vaccines in elderly persons in years of low influenza activityVirol J200855218442371
   PubMed Web of Science ®Google Scholar
• GilchristSANanniALevineOBenefits and effectiveness of administering pneumococcal polysaccharide vaccine with seasonal influenza vaccine: an approach for policymakersAm J Public Health2012102459660522397339
   PubMed Web of Science ®Google Scholar
• NicholKLThe additive benefits of influenza and pneumococcal vaccinations during influenza seasons among elderly persons with chronic lung diseaseVaccine199917Suppl 1S91S9310471189
   PubMed Web of Science ®Google Scholar
• LaxminarayanRMatsosoPPantSAccess to effective antimicrobials: a worldwide challengeLancet20163871001416817526603918
   PubMed Web of Science ®Google Scholar
• BraeterUSchulzMGoffrierBSchulzMIhlePBätzing-FeigenbaumJPneumococcal vaccine in GKV-insured persons in the age range of 60 to 64 years: regionalized analysis on the implementation of the recommendations of the Standing Committee on Vaccination Commission based on national contract medical billing data2016 German. Available from: https://www.versorgungsatlas.de/themen/alle-analysen-nach-datum-sortiert/?tab=6&uid=74Accessed October 11, 2017
   Google Scholar
• Carreno-IbanezLVEsteban-VasalloMDDominguez-BerjonMFCoverage of and factors associated with pneumococcal vaccination in chronic obstructive pulmonary diseaseInt J Tuberc Lung Dis201519673574125946369
   PubMed Web of Science ®Google Scholar
• GieseCMereckieneJDanisKO’DonnellJO’FlanaganDCotterSLow vaccination coverage for seasonal influenza and pneumococcal disease among adults at-risk and health care workers in Ireland, 2013: the key role of GPs in recommending vaccinationVaccine201634323657366227255466
   PubMed Web of Science ®Google Scholar
• GuthmannJPNational vaccination coverage survey, France, January 2011. Influenza vaccination coverage in target groups and measure of vaccine effectiveness: diphtheria-tetanus-poliomyelitis (dTP) and antipneumococcal vaccination coverage in persons aged 65 years old or above2011 French. Available from: http://invs.santepubliquefrance.fr/Publications-et-outils/Rapports-et-syntheses/Maladies-infectieuses/2011/Enquete-nationale-de-couver-ture-vaccinale-France-janvier-2011Accessed October 1, 2017
   Google Scholar
• SteensAVestrheimDFde BlasioBFPneumococcal vaccination in older adults in the era of childhood vaccination: public health insights from a Norwegian statistical prediction studyEpidemics201511243125979279
   PubMed Web of Science ®Google Scholar
• Public Health EnglandPneumococcal polysaccharide vaccine (PPV) coverage report, England, April 2014 to March 20152015 Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/448406/hpr2615_ppv.pdfAccessed October 1, 2017
   Google Scholar
• IpsosPneuVUE: a new view into pneumonia among older adults2016 Available from: https://www.ipsos-mori.com/researchpublications/publications/1816/PneuVUE-A-New-View-into-Pneumonia-Among-Older-Adults.aspxAccessed January 12, 2017
   Google Scholar
• BlasiFAlibertiSBonanniPManteroMOdoneASignorelliCPneumococcal vaccination in adults: recommendations from the Italian Society of Respiratory Medicine (SIMeR) and the Italian Society of Hygiene, Preventive Medicine and Public Health (SItI)Epidemiol Prev2014386 Suppl 2147151 Italian25759360
   PubMedGoogle Scholar
• Portugal Directorate of Disease Prevention and Health Promotion ServicesVaccination against Streptococcus pneumoniae infections in groups at increased risk for invasive pneumococcal disease (IPD): adults (≥18 years of age)2015 Portuguese. Available from: https://www.dgs.pt/directrizes-da-dgs/normas-e-circulares-normativas/norma-n-0112015-de-23062015.aspxAccessed October 11, 2017
   Google Scholar
• Gonzalez-RomoFPicazoJJGarcia RojasAConsensus document on pneumococcal vaccination in adults at risk by age and underlying clinical conditions: 2017 updateRev Esp Quimioter2017302142168 Spanish28198169
   PubMed Web of Science ®Google Scholar
• France Ministry of Social Affairs and HealthCalendar of vaccinations and vaccine recommendations 20172017 French. Available from: http://social-sante.gouv.fr/vaccins-vaccinationAccessed October 1, 2017
   Google Scholar
• Joint Committee on Vaccination and ImmunisationMinutes of the meeting on 4 February 20152015 Available from: https://app.box.com/s/iddfb4ppwkmtjusir2tc/1/2199012147/27417264008/1Accessed October 1, 2017
   Google Scholar
• Standing Committee on Vaccination (STIKO)Recommendations of the Standing Committee on Vaccination (STIKO) at the Robert Koch Institute – effective: August 20162016 Available from: http://www.rki.de/EN/Content/infections/Vaccination/recommandations/34_2016_engl.pdfAccessed October 1, 2017
   Google Scholar
• KimYKLaFonDNahmMHIndirect effects of pneumococcal conjugate vaccines in national immunization programs for children on adult pneumococcal diseaseInfect Chemother201648425726628032483
   PubMedGoogle Scholar
• WeyckerDBornheimerRSheaKMSatoRPeltonSIExcess exacerbations following pneumonia in adults with pre-existing heart failure (HF) or chronic obstructive pulmonary disease (COPD)Poster presented at: 10th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD)June 26–30, 2016Glasgow, Scotland
   Google Scholar
• SuayaJAJiangQBontenMPost-hoc analysis of the 13-valent polysaccharide conjugate vaccine efficacy against vaccine-serotype pneumococcal community acquired pneumonia in at-risk older adultsPoster 634, presented at: the 10th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD)June 29, 2016Glasgow. Scotland
   Google Scholar